Press coverage about Immune Design (NASDAQ:IMDZ) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Immune Design earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.7930258169189 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “sell” rating in a research report on Wednesday, July 4th. ValuEngine raised shares of Immune Design from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, HC Wainwright assumed coverage on shares of Immune Design in a research report on Wednesday, August 29th. They set a “buy” rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $10.80.

Shares of IMDZ traded up $0.05 during trading hours on Monday, reaching $3.50. 134,000 shares of the company traded hands, compared to its average volume of 345,982. The firm has a market capitalization of $168.58 million, a P/E ratio of -2.00 and a beta of 1.77. Immune Design has a 1-year low of $2.80 and a 1-year high of $11.10.

Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.64 million. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. equities research analysts predict that Immune Design will post -1.25 earnings per share for the current year.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Read More: Index Funds

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with's FREE daily email newsletter.